Virax Biolabs Group Ltd (VRAX) USD0.001
Sell:$1.38Buy:$1.39
$0.09
(6.98%)
- This stock can be held in a
Stocks and Shares ISA$0.09
(6.98%)$0.09
(6.98%)Company Information
About this company
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Key people
Key facts
- EPICVRAX
- LocationUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINKYG9495L1251
- Market cap$5.60m
- Employees17
- Shares in issue4.34m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.